The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

bupropion     1-(3-chlorophenyl)-2-(tert...

Synonyms: Elontril, Wellbatrin, Amfebutamon, Elont, Amfebutamona, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of bupropion


Psychiatry related information on bupropion


High impact information on bupropion


Chemical compound and disease context of bupropion


Biological context of bupropion


Anatomical context of bupropion


Associations of bupropion with other chemical compounds


Gene context of bupropion


Analytical, diagnostic and therapeutic context of bupropion


  1. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. Jorenby, D.E., Leischow, S.J., Nides, M.A., Rennard, S.I., Johnston, J.A., Hughes, A.R., Smith, S.S., Muramoto, M.L., Daughton, D.M., Doan, K., Fiore, M.C., Baker, T.B. N. Engl. J. Med. (1999) [Pubmed]
  2. Safety profile of bupropion for chronic obstructive pulmonary disease. Cox, A., Anton, C. Lancet (2001) [Pubmed]
  3. Remission of Crohn's disease on bupropion. Kast, R.E., Altschuler, E.L. Gastroenterology (2001) [Pubmed]
  4. Cardiovascular effects of bupropion in depressed patients with heart disease. Roose, S.P., Dalack, G.W., Glassman, A.H., Woodring, S., Walsh, B.T., Giardina, E.G. The American journal of psychiatry. (1991) [Pubmed]
  5. Sustained-release bupropion for smoking cessation. McAfee, T., France, E. N. Engl. J. Med. (1998) [Pubmed]
  6. Treatment of smokeless tobacco addiction with bupropion and behavior modification. Berigan, T.R., Deagle, E.A. JAMA (1999) [Pubmed]
  7. Treating tobacco dependence: state of the science and new directions. Lerman, C., Patterson, F., Berrettini, W. J. Clin. Oncol. (2005) [Pubmed]
  8. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Weiner, E., Ball, M.P., Summerfelt, A., Gold, J., Buchanan, R.W. The American journal of psychiatry. (2001) [Pubmed]
  9. Prevalence of psychosis, delusions, and hallucinations in clinical trials with bupropion. Johnston, J.A., Lineberry, C.G., Frieden, C.S. The American journal of psychiatry. (1986) [Pubmed]
  10. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Lee, A.M., Jepson, C., Hoffmann, E., Epstein, L., Hawk, L.W., Lerman, C., Tyndale, R.F. Biol. Psychiatry (2007) [Pubmed]
  11. Crohn's disease remission on bupropion. Kane, S., Altschuler, E.L., Kast, R.E. Gastroenterology (2003) [Pubmed]
  12. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Tashkin, D., Kanner, R., Bailey, W., Buist, S., Anderson, P., Nides, M., Gonzales, D., Dozier, G., Patel, M.K., Jamerson, B. Lancet (2001) [Pubmed]
  13. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Leverich, G.S., Altshuler, L.L., Frye, M.A., Suppes, T., McElroy, S.L., Keck, P.E., Kupka, R.W., Denicoff, K.D., Nolen, W.A., Grunze, H., Martinez, M.I., Post, R.M. The American journal of psychiatry. (2006) [Pubmed]
  14. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Wagena, E.J., Knipschild, P.G., Huibers, M.J., Wouters, E.F., van Schayck, C.P. Arch. Intern. Med. (2005) [Pubmed]
  15. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. Ahluwalia, J.S., Harris, K.J., Catley, D., Okuyemi, K.S., Mayo, M.S. JAMA (2002) [Pubmed]
  16. Antidepressant-associated mania: a controlled comparison with spontaneous mania. Stoll, A.L., Mayer, P.V., Kolbrener, M., Goldstein, E., Suplit, B., Lucier, J., Cohen, B.M., Tohen, M. The American journal of psychiatry. (1994) [Pubmed]
  17. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Little, J.T., Ketter, T.A., Kimbrell, T.A., Dunn, R.T., Benson, B.E., Willis, M.W., Luckenbaugh, D.A., Post, R.M. Biol. Psychiatry (2005) [Pubmed]
  18. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Loboz, K.K., Gross, A.S., Williams, K.M., Liauw, W.S., Day, R.O., Blievernicht, J.K., Zanger, U.M., McLachlan, A.J. Clin. Pharmacol. Ther. (2006) [Pubmed]
  19. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? Trivedi, M.H., Rush, A.J., Carmody, T.J., Donahue, R.M., Bolden-Watson, C., Houser, T.L., Metz, A. The Journal of clinical psychiatry. (2001) [Pubmed]
  20. The "bupropion for smoking cessation" trial from a family practice perspective. Caplan, B.J. Arch. Intern. Med. (2005) [Pubmed]
  21. Bone density loss in Crohn's disease: role of TNF and potential for prevention by bupropion. Kast, R.E., Altschuler, E.L. Gut (2004) [Pubmed]
  22. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Laizure, S.C., DeVane, C.L., Stewart, J.T., Dommisse, C.S., Lai, A.A. Clin. Pharmacol. Ther. (1985) [Pubmed]
  23. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Hogeland, G.W., Swindells, S., McNabb, J.C., Kashuba, A.D., Yee, G.C., Lindley, C.M. Clin. Pharmacol. Ther. (2007) [Pubmed]
  24. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Nomikos, G.G., Damsma, G., Wenkstern, D., Fibiger, H.C. Neuropsychopharmacology (1989) [Pubmed]
  25. Bupropion: a review of its mechanism of antidepressant activity. Ascher, J.A., Cole, J.O., Colin, J.N., Feighner, J.P., Ferris, R.M., Fibiger, H.C., Golden, R.N., Martin, P., Potter, W.Z., Richelson, E. The Journal of clinical psychiatry. (1995) [Pubmed]
  26. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Hesse, L.M., He, P., Krishnaswamy, S., Hao, Q., Hogan, K., von Moltke, L.L., Greenblatt, D.J., Court, M.H. Pharmacogenetics (2004) [Pubmed]
  27. Treatment choice after one antidepressant fails: a survey of northeastern psychiatrists. Nierenberg, A.A. The Journal of clinical psychiatry. (1991) [Pubmed]
  28. Smokeless tobacco and cardiovascular risk. Gupta, R., Gurm, H., Bartholomew, J.R. Arch. Intern. Med. (2004) [Pubmed]
  29. REM sleep enhancement by bupropion in depressed men. Nofzinger, E.A., Reynolds, C.F., Thase, M.E., Frank, E., Jennings, J.R., Fasiczka, A.L., Sullivan, L.R., Kupfer, D.J. The American journal of psychiatry. (1995) [Pubmed]
  30. Bupropion does not antagonize cardiovascular actions of clonidine in normal subjects and spontaneously hypertensive rats. Cubeddu, L.X., Cloutier, G., Gross, K., Grippo, R., Tanner, L., Lerea, L., Shakarjian, M., Knowlton, G., Stat, M., Harden, T.K. Clin. Pharmacol. Ther. (1984) [Pubmed]
  31. Use of bupropion in combination with serotonin reuptake inhibitors. Zisook, S., Rush, A.J., Haight, B.R., Clines, D.C., Rockett, C.B. Biol. Psychiatry (2006) [Pubmed]
  32. MALDI-TOF Mass Spectrometry for Multiplex Genotyping of CYP2B6 Single-Nucleotide Polymorphisms. Blievernicht, J.K., Schaeffeler, E., Klein, K., Eichelbaum, M., Schwab, M., Zanger, U.M. Clin. Chem. (2007) [Pubmed]
  33. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Lerman, C., Jepson, C., Wileyto, E.P., Epstein, L.H., Rukstalis, M., Patterson, F., Kaufmann, V., Restine, S., Hawk, L., Niaura, R., Berrettini, W. Neuropsychopharmacology (2006) [Pubmed]
  34. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Jefferson, J.W., Pradko, J.F., Muir, K.T. Clinical therapeutics. (2005) [Pubmed]
  35. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Faucette, S.R., Hawke, R.L., Shord, S.S., Lecluyse, E.L., Lindley, C.M. Drug Metab. Dispos. (2001) [Pubmed]
  36. Cocaine alters catalase activity in prefrontal cortex and striatum of mice. Macêdo, D.S., de Vasconcelos, S.M., dos Santos, R.S., Aguiar, L.M., Lima, V.T., Viana, G.S., de Sousa, F.C. Neurosci. Lett. (2005) [Pubmed]
  37. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. Pierce, J.P., Gilpin, E.A. JAMA (2002) [Pubmed]
  38. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. Hatsukami, D.K., Rennard, S., Patel, M.K., Kotlyar, M., Malcolm, R., Nides, M.A., Dozier, G., Bars, M.P., Jamerson, B.D. Am. J. Med. (2004) [Pubmed]
  39. A double-blind study of bupropion and placebo in depression. Feighner, J.P., Meredith, C.H., Stern, W.C., Hendrickson, G., Miller, L.L. The American journal of psychiatry. (1984) [Pubmed]
  40. Therapeutic drug monitoring of bupropion. Preskorn, S.H., Fleck, R.J., Schroeder, D.H. The American journal of psychiatry. (1990) [Pubmed]
  41. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Tonstad, S., Farsang, C., Klaene, G., Lewis, K., Manolis, A., Perruchoud, A.P., Silagy, C., van Spiegel, P.I., Astbury, C., Hider, A., Sweet, R. Eur. Heart J. (2003) [Pubmed]
WikiGenes - Universities